NOVARTIS se abre a China...

Novartis on Tuesday revealed plans to invest $1bn to expand its Shanghai laboratories and make China the third pillar of its global research and development capabilities.

Daniel Vasella, chairman, said the Swiss drugs group would build a new campus in Shanghai to house its research activities, which would employ 1,000 scientists in five years’ time.

.../...

The move comes after significant investments in recent years by several big western companies, including AstraZeneca, Roche and GlaxoSmithKline, seeking to recruit local expertise, take advantage of lower costs and expand their presence in one of the world’s fastest-growing drugs markets. (Ver...)